Revelation Biosciences, Inc. — 2021 Form 10-K
Reporting period: Year ended December 31, 2021. The audited financial statements are for Petra Acquisition, Inc., Revelation’s SPAC predecessor, not for Old Revelation’s clinical-stage biotech operations. The business combination closed January 10, 2022; Old Revelation’s financial information is referenced in a separate filing and is not included here. Accordingly, Petra’s results below should not be read as Revelation’s operating results.
Financial results and position
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | None | None |
| General and administrative expense | $3.09 million | $145,492 |
| Net loss | $2.13 million | $1.63 million |
| Operating cash used | $725,618 | $216,664 |
| Cash outside the trust account at year-end | $78,532 | $11,734 |
| Cash held in trust at year-end | $48.30 million | $73.51 million |
| Current liabilities | $5.49 million | $3.43 million |
| Total liabilities | $8.40 million | $6.34 million |
| Working capital deficiency | Approximately $5.40 million | Not stated |
The net loss included a $1.01 million non-cash gain from the change in fair value of warrant liabilities; operating costs were primarily professional fees and insurance. Cash used in operations increased year over year, while G&A expense rose substantially. Year-end common stock subject to possible redemption was presented as temporary equity at $47.81 million. No long-term debt or off-balance-sheet arrangements were reported. The filing gives no meaningful product margins, commercial revenue, or operating cash-flow measures for Old Revelation.
Business context, changes, and outlook
Old Revelation describes itself as a clinical-stage company developing innate-immune therapeutics and diagnostics: REVTx-99a for respiratory viral infections, REVTx-99b for allergic rhinitis and nasal congestion, REVTx-200 as a potential intranasal vaccine adjunct, and REVDx-501 as a rapid respiratory-virus diagnostic. None was approved for commercial sale, and the company had no product revenue. Petra’s 2021 activities were those of a blank-check company—formation, IPO, target search, and preparation for the combination.
The January 2022 combination was accounted for as a reverse recapitalization, with Old Revelation treated as the accounting acquirer; post-combination financial reporting is therefore expected to reflect Old Revelation’s historical operations. Petra’s 2021 trust balance fell year over year, including $25.7 million paid for redemptions in October 2021. The 10-K reports further redemptions at the January 2022 closing of approximately $35.5 million, a $7.76 million gross PIPE completed in January, and a $7.6 million escrow connected with the forward share purchase agreement. These subsequent events are not included in the December 31, 2021 balance sheet.
Management said the full data package from REVTx-99a’s Phase 2b influenza challenge study was expected by the end of Q2 2022 to inform future development. The company reported on March 30, 2022 that the primary endpoint—viral-load area under the curve—did not meet statistical significance. REVTx-99b Phase 1b topline data were expected in the second half of 2022. Management planned further REVDx-501 development and FDA submission after development was complete, and intended to pursue vaccine-company relationships and nonclinical work for REVTx-200. These are forward-looking plans, not assured outcomes.
Liquidity, risks, contingencies, and unusual items
- Funding and liquidity: Petra had only $78,532 of cash outside the trust and a working capital deficit of about $5.40 million at year-end, alongside $750,000 of promissory notes bearing interest at 2% per month. The reported $48.30 million trust balance was associated with the SPAC transaction and should not be treated as unrestricted operating cash available to the post-combination business.
- Post-year-end financing and obligations: The January 2022 PIPE generated approximately $7.76 million gross before fees and expenses and included common shares and warrants. The company also entered an $825,000 insurance premium financing agreement. These subsequent events affect liquidity but are not 2021 results.
- Clinical and regulatory risk: The lead antiviral study missed its primary endpoint; later-stage efficacy, safety, regulatory acceptance of foreign clinical data, and the timing and cost of further studies remain uncertain. No product was approved, and the company warned it expects continued losses and may need additional financing.
- Supply and commercialization: The company relies on third parties for development and manufacturing and identified Avanti Polar Lipids as the sole PHAD supplier, without a long-term supply agreement. It had no sales or marketing organization and anticipated needing partners or substantial investment to commercialize products.
- Legal contingency: LifeSci Capital sued in February 2022 seeking approximately $2.7 million cash and $2.6 million in equity for disputed banking and advisory fees. The company disputed the amount; the filing does not state a resolution.
- Accounting and controls: Changes in the fair value of private-warrant liabilities are non-cash and may make reported earnings volatile. Management concluded disclosure controls were ineffective at December 31, 2021 due to a material weakness, while separately stating that internal control over financial reporting was effective under its assessment; the filing provides these distinct conclusions and they merit review.
- Global Health Agreement: For six years from December 31, 2020, if specified products are approved, the company committed to supply eligible purchasers in designated lower- and middle-income countries at no more than 30% above cost of goods, make up to 20% of annual unit sales available, and allocate $50,000 annually to related training work.
Most important facts for investors to verify
- Obtain and review Old Revelation’s separate financial statements, cash runway, and post-combination liquidity; Petra’s 2021 SPAC financials do not show the biotech business’s 2021 operating performance.
- Check the final REVTx-99a Phase 2b data and management’s subsequent decision on the program after the failed primary endpoint.
- Reconcile post-closing cash proceeds, redemptions, the Meteora share repurchase, PIPE costs and warrant dilution, and the company’s available cash after these items.
- Track the LifeSci fee litigation, including any settlement, judgment, or recognized liability.
- Review remediation of the disclosed material weakness and clarify the basis for the different disclosure-controls and internal-control conclusions.
- Confirm product-development timelines, funding needs, PHAD supply arrangements, and regulatory plans against later company filings; the 10-K’s stated milestones are expectations, not guarantees.